1. A novel class of Ribosome Modulating Agents (RMAs) target MYC driven SCLC and synergize with DNA intercalating agents. (October 2022) Authors: Badarinarayana, V.; Brait, M.; Terzo, E.; Lima, D.G.; Ugurlu, M.T.; Apte, S.; Padhye, S.; Rashed, S.; Austin, W.F.; Wang, C.; Caponegro, M.; Clark, R.B.; Sidransky, D.; Modur, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel class of Ribosome Modulating Agents (RMAs) targets ribosome heterogeneity in a subset of colorectal cancers. (October 2022) Authors: Badarinarayana, V.; Terzo, E.; Apte, S.; Padhye, S.; Rashed, S.; Austin, W.; Caponegro, M.; Reddy, A.; Wang, C.; Clark, R.; Sidransky, D.; Modur, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗